6.89 +0.02 (0.29%)
After hours: 5:16PM EDT
Previous Close | 7.12 |
Open | 7.22 |
Bid | 6.80 x 900 |
Ask | 6.89 x 900 |
Day's Range | 6.82 - 7.31 |
52 Week Range | 5.04 - 20.50 |
Volume | 175,102 |
Avg. Volume | 298,331 |
Market Cap | 302.364M |
Beta (5Y Monthly) | -0.31 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.44 |
Earnings Date | May 12, 2021 - May 17, 2021 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 16.57 |
Dan Menichella, Kaleido CEO, joins Yahoo Finance’s Anjalee Khemlani, Alexis Christoforous and Kristin Myers to discuss the utilization of oral therapeutic KB109 for COVID-19 and emerging variants.
CytoDyn (CYDY) submits a new protocol with the regulatory body in the United States to study a higher dose of leronlimab for severely-infected COVID-19 patients.
The biotech sector gains prominence with new product approvals from bluebird (BLUE)/Bristol Myers Squibb (BMY) and other coronavirus updates.